Price to Sales (P/S)
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Product sales1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
| Mar 13, 2019 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Moderna Inc. Annual Report.
- Share Price Trend
- There was a gradual increase in share price from $19.97 in March 2019 to $26.16 in February 2020. A significant surge occurred in the following year, with the share price reaching $154.81 by February 2021. Subsequently, the price showed a moderate decline, decreasing to $151.33 in February 2022 and further to $139.26 in February 2023. The latest available data from February 2024 indicates a more pronounced drop to $96.46.
- Sales Per Share Evolution
- Sales per share data is unavailable prior to February 2021. Starting from 2021, sales per share was reported at $0.5 and then sharply increased to $43.87 in February 2022. This upward trend continued to $47.72 in February 2023. However, the most recent figure from February 2024 shows a significant decrease to $17.46.
- Price-to-Sales (P/S) Ratio Dynamics
- The price-to-sales ratio data begins in February 2021 with an extraordinarily high ratio of 309.64, indicating a substantially high share price relative to sales per share at that time. In the following year, this ratio dramatically decreased to 3.45, then to 2.92 in February 2023, reflecting improved sales relative to share price. The ratio increased again to 5.52 in February 2024, suggesting a relative increase in share price or decrease in sales per share compared to the previous year.
- Summary of Financial Trends
- The share price experienced a steep rise in early years followed by a notable decline in the last two years. Sales per share followed an upward trajectory after 2021 but faced a setback in the most recent year. The P/S ratio data illustrates an initial period of extreme market valuation, which normalized substantially but showed some volatility in the latest period. Overall, the data points to a peak in share price and sales performance around 2021-2023, followed by a period of correction or adjustment in 2024.
Comparison to Competitors
Moderna Inc., P/S, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | |||||||||||||
| Feb 24, 2023 | |||||||||||||
| Feb 25, 2022 | |||||||||||||
| Feb 26, 2021 | |||||||||||||
| Feb 27, 2020 | |||||||||||||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 23, 2024 | ||
| Feb 24, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Feb 27, 2020 | ||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., P/S, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Feb 23, 2024 | ||
| Feb 24, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Feb 27, 2020 | ||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).